FIIN-3
CAS No. 1637735-84-2
FIIN-3 ( FIIN3; FIIN 3; FIIN-3 )
Catalog No. M17353 CAS No. 1637735-84-2
FIIN-3 is an irreversible inhibitor of FGFR.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 68 | In Stock |
|
5MG | 110 | In Stock |
|
10MG | 178 | In Stock |
|
25MG | 399 | In Stock |
|
50MG | 590 | In Stock |
|
100MG | 840 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFIIN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionFIIN-3 is an irreversible inhibitor of FGFR.
-
DescriptionFIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. FIIN-3 is the first inhibitor that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. FIIN-3 bound with FGFR4 V550L and EGFR L858R.
-
SynonymsFIIN3; FIIN 3; FIIN-3
-
PathwayChromatin/Epigenetic
-
TargetSirtuin
-
RecptorFGFR1; FGFR2; FGFR3; FGFR4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1637735-84-2
-
Formula Weight691.61
-
Molecular FormulaC34H36Cl2N8O4
-
Purity98%
-
SolubilityDMSO : 10 mg/mL 14.46 mM;
-
SMILESC(=O)(C=C)Nc1ccc(cc1)CN(c1ncnc(c1)Nc1ccc(cc1)N1CCN(CC1)C)C(=O)Nc1c(c(cc(c1Cl)OC)OC)Cl
-
Chemical NameN-(4-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)ureido)methyl)phenyl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tan L et al. Proc Natl Acad Sci U S A, 2014 Nov 11, 111(45):E4869-77
molnova catalog
related products
-
SRT 1460
SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM.
-
JGB1741
JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.
-
SirT1 enhancer A03
SirT1 enhancer A03 is a specific, orally bioavailable, brain penetrant apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer.